Drug Trial Radar · NCT04446351
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
107
Actual
Start
Jun 25, 2020
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- 23andMe, Inc.; iTeos Therapeutics
- First posted
- Jun 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. In addition, dostarlimab will be given as monotherapy (Arm D); and in combination with belrestotug (Arm E); and with GSK6097608 + belrestotug (Arm F) in Japanese and Chinese participants. The study may assess the PK/PD cohorts for Arm E and/or Arm F in participants outside of China and Japan. Additionally, dostarlimab will be given in combination with cobolimab in Japanese participants. Drug name mentioned as belrestotug, GSK4428859A and EOS884448 are interchangeable for the same compound. In the rest of the document, the drug will be referred to as belrestotug.
Conditions
- Neoplasms
Interventions
GSK6097608Drug
GSK6097608 will be administered as an IV infusion.
DostarlimabDrug
Dostarlimab will be administered as an IV infusion.
CobolimabDrug
Cobolimab will be administered as an IV infusion.
BelrestotugDrug
Belrestotug will be administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to Day 21
- Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to 2 years
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.